Business

Feliza Mirasol is the science editor for 

Articles

The Vacaville, Calif., site acquisition gives Lonza one of the largest biologics manufacturing sites for mammalian cell-based therapies worldwide.

Roche Sells Large-Scale Biologics Manufacturing Site in US to Lonza for $1.2 Billion

Ricoh aims to create novel disease models for R&D using ERS Genomics’ CRISPR/Cas9 genome editing technology.

Ricoh and ERS Genomics Enter License Agreement for CRISPR/Cas9 Technology

Mapp Biopharmaceutical will use ProBioGen’s GlymaxX technology for the development of an afucosylated antibody against Marburg virus infection

Mapp Biopharmaceutical Teams Up with ProBioGen and to Develop Antibody Against Marburg Virus Disease

In a new manufacturing pact, Chime Biologics will produce DT-7012, Domain Therapeutics' antibody candidate for treating cancer that will soon be entering Phase I studies.

Chime Biologics to Manufacture Novel Antibody Cancer Immunotherapy for Domain Therapeutics

The European company has seen its business increase by 47% in North America.

Bormioli Pharma’s Business Expands in United States

Johnson & Johnson’s $2 billion acquisition of Ambrx boosts its pipeline of next-generation ADCs for cancer treatment.

J&J Completes $2 Billion Ambrx Acquisition, Boosts Pipeline for Next-Gen ADCs

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

New plans laid out by AstraZeneca will see £650 million ($828 million) be invested into the UK.

AstraZeneca Set to Boost the UK’s Life Sciences Sector with Investment Plans

Under a global license and collaboration agreement, AbbVie and OSE Immunotherapeutics will aim to develop OSE-230, a mAb for treating chronic inflammation.

AbbVie Partners with OSE Immunotherapeutics on Novel mAb for Chronic Inflammation

 in 2014, Adam Goulder has over 30 years' experience within the maintenance engineering and asset management sectors including Pharmaceutical and Medical Devices manufacturing. As Head of Project Management and a Principal Consultant Adam oversees the management and implementation of enterprise asset management solutions to a wide range of organisations across the Pharmaceutical, Medical Devices, Healthcare, Logistics, Facilities Management, Utilities, Oil & Gas, and Transportation sectors. Adam is a Chartered Engineer, holds an MSc in Maintenance Engineering and Asset Management from the University of Manchester and is a member of the International Society of Pharmaceutical Engineers.

Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.

Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?

Nona Biosciences and Boostimmune will collaborate to develop ADCs against novel targets using Nona’s proprietary platform technology.

Business News